Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)

Pagidipati, Neha; Navar, Ann; Pieper, Karen; Green, Jennifer; Bethel, M.; Armstrong, Paul; Josse, Robert; McGuire, Darren; Lokhnygina, Yuliya; Cornel, Jan; Halvorsen, Sigrun; Strandberg, Timo; DELİBAŞI, TUNCAY; Holman, Rury; Peterson, Eric

doi:10.1161/circulationaha.117.027252

Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)

Pagidipati N. J., Navar A. M., Pieper K. S., Green J. B., Bethel M. A., Armstrong P. W., ...More

CIRCULATION, vol.136, no.13, pp.1193-1205, 2017 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 136 Issue: 13
Publication Date: 2017
Doi Number: 10.1161/circulationaha.117.027252
Journal Name: CIRCULATION
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1193-1205
Open Archive Collection: AVESIS Open Access Collection
Hacettepe University Affiliated: Yes

Abstract

BACKGROUND: Intensive risk factor modification significantly improves outcomes for patients with diabetes mellitus and cardiovascular disease. However, the degree to which secondary prevention treatment goals are achieved in international clinical practice is unknown.